Published online before print October 9, 2006, doi: 10.1161/01.HYP.0000246306.61289.d8
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;48:e115.)
© 2006 American Heart Association, Inc.
Letters to the Editor |
Blood Pressure in Mutant Rats Lacking the 5-Hydroxytryptamine Transporter
Hubrecht Laboratory, Utrecht, The Netherlands
Department of Nephrology and Immunology, University of Alberta, Alberta, Canada
Department of Psychoneuropharmacology, Radboud University, Nijmegen, The Netherlands
Hubrecht Laboratory, Utrecht, The Netherlands
Department of Nephrology and Hypertension, University Medical Centre Utrecht, Utrecht, The Netherlands
Although 5-HT uptake inhibitors are widely used as antidepressants, the role of 5-HT in the control of systemic blood pressure is far from clear.1 In a recent issue of Hypertension, Ni et al reported that 5-hydroxytryptamine (5-HT) transporter (SERT) expression was increased, whereas SERT function was decreased in aorta of rats with DOCA salt and N
-nitro-L-arginine (L-NNA)-induced hypertension.2 We have observed that several 5-HT receptors are induced in leukocytes of hypertensive patients.3 These 2 observations could point at a functional response of the serotonin system to counter prohypertensive forces. We used the recently generated and unique SERT knockout rat to investigate whether the constitutive absence of SERT affected blood pressure and aggravated the development of hypertension and renal damage on NO synthesis inhibition.
A target-selected N-ethyl-N-nitrosourea–driven mutagenesis approach was used in Wistar rats to inactivate genes.4 High-throughput resequencing of genes of interest in a library of mutant rats resulted in the identification of a premature stop codon in the serotonin transporter. We have established that the homozygous SERT knockout (SERT–/–) rat completely lacks functional SERT in the brain (data not shown). Furthermore, 5-HT in blood platelets, which plays a crucial role in vasoconstriction and has mitogenic activity in vascular smooth muscle, was almost completely lacking in SERT–/– rats (Figure).
|
To characterize the SERT–/– rat with respect to the cardiovascular system, we measured systolic blood pressure (SBP) in female SERT–/–, SERT+/–, and SERT+/+ rats under control conditions and during chronic L-NNA administration (500 mg/L of drinking water5). Under control conditions, there were no differences in SBP between genotypes. Left ventricular (LV) weight/body weight and increases in SBP and LV/body weight during L-NNA (both P<0.01; 2-way ANOVA) were similar in all 3 of the groups (Table). Furthermore, under control conditions or L-NNA treatment, no differences were found in proteinuria, plasma urea and creatinine, and renal morphology (data not shown).
|
SERT-deficient mice also display normal blood pressure, although LV weight is reduced.6 It is at this functional level that the present data complement the data presented by Ni et al.2 From our analysis in the SERT–/– rat, it seems that the integrative role for SERT on blood pressure control by systemic hemodynamics and by the kidney to protect against the hypertensive effects of NO-shortage is limited. Furthermore, a protective role against glomerular damage caused by NO deficiency could not be substantiated.
 |
Acknowledgments |
|---|
Disclosures
None.
|
References |
|---|
 Top References |
|---|
- Watts SW. 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (Lond). 2005; 108: 399–412.[Medline] [Order article via Infotrieve]
- Ni W, Lookingland K, Watts SW. Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and N{omega}-nitro-L-arginine but not spontaneously hypertensive rats. Hypertension. 2006; 48: 134–140.
[Abstract/Free Full Text] - Chon H, Gaillard CA, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B. Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension. 2004; 43: 947–951.
[Abstract/Free Full Text] - Smits BM, Mudde JB, van de Belt J, Verheul M, Olivier J, Homberg J, Guryev V, Cools AR, Ellenbroek BA, Plasterk RH, Cuppen E. Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. Pharmacogenet Genomics. 2006; 16: 159–169.[Medline] [Order article via Infotrieve]
- Attia DM, Verhagen AM, Stroes ES, van Faassen EE, Grone HJ, De Kimpe SJ, Koomans HA, Braam B, Joles JA. Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2001; 12: 2585–2593.
[Abstract/Free Full Text] - Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000; 105: 1555–1562.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. E. Linder, W. Ni, T. Szasz, R. Burnett, J. Diaz, T. J. Geddes, D. M. Kuhn, and S. W. Watts A Serotonergic System in Veins: Serotonin Transporter-Independent Uptake J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 714 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Linder, J. Diaz, W. Ni, T. Szasz, R. Burnett, and S. W. Watts Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1745 - H1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ni, K. Lookingland, and S. W. Watts Response to Blood Pressure in Mutant Rats Lacking the 5-Hydroxytryptamine Transporter Hypertension, December 1, 2006; 48(6): e117 - e117. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||